PHP123 PHARMACY NETWORK DEVELOPMENT DURING ECONOMIC TRANSITION IN POLAND
Tuszyska M, Hermanowski TR, Feliksiak H Medical University of Warsaw, Warsaw, Poland OBJECTIVES: To analyze the effects of liberalization of regulations, concerning establishment of pharmacies and pharmacy points in Poland after 1989. METHODS: The data on the number of pharmacies and pharmacy points, used for the analysis were collected by mail survey completed by all regional pharmaceutical supervision authorities. Population data were sourced from the statistical yearbook of Poland. RESULTS:
During economic transition Poland was one of few European Union countries, where the number of pharmacies was not regulated within a given area. Therefore, their numbers increased rapidly, reaching 12.153 private pharmacies and 1.397 private pharmacy points in 2009. This means that in 2009 one pharmacy served 3.127 people. Before privatization process started in 1989, all retail pharmacies were managed by a state-owned enterprise "Cefarm". Since then, the regulations have changed and the number of pharmacies started to grow. The main reasons of this trend was a regulation stipulating that permission to establish a pharmacy can be granted to any private or legal person, disregarding professional education of that person. Pharmacy owner was only required to employ a qualifi ed pharmacist, responsible for managing the pharmacy. Another major institutional change was introduced by the Pharmaceutical Law, voted October 10, 1991, which authorized establishment of pharmacy points. In spite of the general trend, in some poor provinces of Poland the number of pharmacies decreased. June 1, 2010, European Court of Justice ruled that the right to own and operate a pharmacy may be reserved exclusively for pharmacists and that demographic or geographic criteria may be used in the process of issuing permits to operate pharmacies. CONCLUSIONS: Currently, the Polish Ministry of Health has to propose amendments to the Pharmaceutical Law, implementing the above mentioned criteria.
PHP124

DESCRIPTION OF THE PRICING AND REIMBURSEMENT SYSTEM IN THE CZECH REPUBLIC
Petrikova A 1 , Dolezal T 2 , Lamka J 3 , Klimes J 4 1 VFU Brno, Brno, Czech Republic; 2 Institute for Health Economics and Technology Assessment, Prague, Czech Republic; 3 Charles University, Prague, Czech Republic; 4 Charles University, Hradec Kralove, Czech Republic OBJECTIVES: To investigate changes realized in the Czech pricing and reimbursement system since January 2008 and to describe the current development of this system.
METHODS:
We described the legal framework defi ning the Czech system (Act No. 48/1997 Coll. as amended by the Act No. 261/2007 Coll. on Public Health Insurance) as well as evaluation of the current system from the literature and reports provided by the State Institute for Drug Control (SUKL). RESULTS: In order to increase transparency according to EU Transparency Directive and to set fairly-defi ned deadlines the competencies for the pricing and reimbursement system were merged from Ministries of Finances and Ministry of Health (MoH) under one responsible institution-SUKL. The pricing rules were fully changed-the maximum price is set based as the mean value of all available ex-factory prices in the reference countries (Estonia, France, Italy, Lithuania, Hungary, Portugal, Greece and Spain). The reference reimbursement system contains 251 reference groups of therapeutically interchangeable products with similar clinical effi cacy and safety (should be updated annually by MoH). Medicinal products included in one reference group have the main common therapeutic indication in the same reimbursement level which is calculated on the basis of retail prices in all EU countries. The cheapest price for equipotent dose is chosen and re-counted according to local pharmacy and wholesaler margins and value added taxes. In compliance with new legislation the pharmacoeconomic criteria (cost-effectiveness evaluation and budget impact analysis) should be taken into account. There is possibility of extra bonus of basic reimbursement for better effi cacy, safety, dosing schedule, compliance, etc. CONCLUSIONS: The system has gone through dramatic changes in last two years and some aspects are still facing challenges. Although the new system should reassessed all medicines covered in the country till 2008, currently there are only 20% revised (April 2010).
HEALTH CARE USE & POLICY STUDIES -Risk-Sharing/Performance-Based Scheme/Agreements
PHP125 TRENDS IN UK-BASED PATIENT ACCESS SCHEMES: FINANCIAL-BASED VERSUS OUTCOMES-BASED AGREEMENTS
Woods RM, Johnson KI Complete Market Access, Macclesfi eld, Cheshire, UK OBJECTIVES: Whilst patient access schemes (PAS) are not a new concept, they are clearly receiving increasing attention. The fi rst notable PAS, devised to improve access to beta interferons for multiple sclerosis, was an outcomes-based scheme designed to overcome uncertainty in long-term clinical and cost-effectiveness. It is the nature of the uncertainty that drives the design of PAS, but is there a trend towards which schemes are more popular? We analyzed the design of published PAS employed in the UK in order to determine if outcomes-based or fi nancial-based schemes predominate. METHODS: Published PAS were identifi ed from health technology assessment websites (e.g. the National Institute for Health and Clinical Excellence and Scottish Medicines Consortium), literature searching of ISPOR conference abstracts, and searching of 'patient access scheme' or 'risk-sharing scheme,' using internet search engines. PAS identifi ed were categorised as fi nancial-based (price-or volume-based agreements) or outcomes-based schemes. Desk research was the performed to identify the preference for each type of scheme, in terms of uptake by UK Primary Care Trusts. RESULTS: Seventeen published PAS were identifi ed from the literature search, from 2002 until 2010. Categorization of PAS as fi nancial-based versus outcomes-based showed that schemes were balanced, but favoured fi nancial-based schemes (59% versus 41%, respectively). The uptake of fi nancial-based schemes was found to be higher than outcomes-based schemes due to administrative burden posed by schemes which rely on the measurement and reporting of clinical outcomes. CONCLUSIONS: PAS were pioneered by the beta interferon outcomes-based scheme for multiple sclerosis, 2002. Since then, published UK-based schemes favour price or volume-based schemes, a trend illustrated by two of the three newest schemes published in 2010. The simplicity of fi nancial-based agreements, combined with poor health care system uptake of outcomes-based schemes and the demand for value-based pricing, suggests that this trend is set to continue.
PHP126 PATIENT ACCESS SCHEMES (PAS) IN THE UK COMING OF AGE: WHAT IMPACT WILL THEY HAVE ON OTHER EU COUNTRIES LIKE ITALY?
Kirpekar S, Mallinson M, White R, Gannedahl A Double Helix Consulting Group, London, UK OBJECTIVES: Although patient access schemes (PAS) have historically been implemented for high-cost oncology drugs, recent schemes for chronic diseases like rheumatoid arthritis (RA) have been seen in the UK. This study tries to understand how the shift in PAS from being accepted by payers only for short-term oncology drugs to those for chronic diseases like RA in the UK will infl uence the situation in Italy, where PAS are known to be widespread. METHODS: This study used qualitative telephone interviews to analyze trends in the UK (n = 7) and Italy (n = 7). Interviews were conducted in tertiary hospitals as well as local, regional and national level reimbursement authorities involving fi nancial and clinical stakeholders, and key individuals in the implementation of the scheme. Importance of a number of variables affecting new PAS was ranked. RESULTS: Budget-holders in both markets were seen to be sceptical about the impact on long-term budgets due to the move towards PAS for chronic conditions. Of the 14 stakeholders interviewed, 9 said that such schemes in chronic conditions might help companies access markets with lesser clinical evidence on the basis of the class-effect of the drugs and the risk-sharing nature of the schemes. Monitoring of the outcomes on implementation was thought to be crucial. CONCLU-SIONS: In Italy, increase in PAS for chronic diseases will help drug companies bring drugs to the market earlier. On the other hand, the payers will see this as an increased burden on their budgets as it will mean funding longer term treatment. Also, due to recent issues with monitoring of outcomes in PAS in the UK, their future needs reconsideration. This move of PAS towards chronic conditions is expected to increase the impact that post-marketing monitoring will have on market access for expensive 'me-too' drugs in the EU.
PHP127 ADOPTING A FINANCIAL RISK-SHARING SCHEME FOR NEW TECHNOLOGIES ADDED TO THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL: STAKEHOLDERS' STATED INCENTIVES AND DISINCENTIVES
Hammerman A, Feder-Bubis P, Greenberg D Ben Gurion University of the Negev, Beer-Sheva, Israel OBJECTIVES: To explore major stakeholders' incentives and disincentives to adopt a fi nancial risk-sharing mechanism regarding budget-impact estimates of adopting new technologies in the Israeli National List of Health Services (NLHS). According to the proposed scheme, HMOs will be partially compensated by the pharmaceutical and medical device industry if actual use of a technology is substantially higher than what was projected and allocated. On the other hand, HMOs will partially refund the government for budgets allocated to specifi c technologies that were not fully used. These unused budgets will be used for adopting other technologies in subsequent years. METHODS: Using a semi-structured protocol, we interviewed major stakeholders involved in the process of updating the NLHS (N = 31). Interviewees included government offi cials, senior managers in the country's four HMOs, pharmaceutical industry executives, and health economists. We inquired into the interviewee's view towards our proposed risk-sharing mechanism, and their opinion on the other stakeholders' incentives to accept or object the proposed scheme. RESULTS: Our interviews revealed a wide range of incentives, disincentives, and barriers for adopting the risk-sharing mechanism. There was no consensus on what would be the different stakeholders' incentives and disincentives for adopting the proposed mechanism, even within the various stakeholders groups themselves. Most interviewees from the HMOs and the pharmaceutical industry supported the proposed risk-sharing agreement. Among government offi cials, the Ministry of Finance decision-makers tended to object to the proposed mechanism, while Ministry of Health executives usually supported the scheme, but believed that the pharmaceutical industry will not support this risksharing agreement. CONCLUSIONS: Since the success of implementing a risk-sharing mechanism depends mainly on its perception as a win-win situation for all stakeholders, we recommend that decision-makers consider the different incentives and disincentives exposed in our interviews, when implementing such a mechanism.
HEALTH CARE USE & POLICY STUDIES -Beyond Drug Interventions
PHP128 THE USE OF HEALTH PROMOTION INITIATIVES BY MUNICIPALITIES IN BELGIUM. A RETROSPECTIVE OBSERVATIONAL STUDY
Verhaeghe N, Barbe T, Annemans L Ghent University, Ghent, Belgium OBJECTIVES: Growing attention is currently given to preventive health care. Prevention can decline the appearance of several diseases and as a consequence lead to a decrease of health care expenses. The aim of this study was to evaluate if municipalities in Belgium currently are using intervention strategies for optimizing the health behavior of citizens. Special attention was given to what extent certain high-risk groups are reached. METHODS: The design consisted of a retrospective observational design. The general services or-if existing-the sports services of 570 Belgian cities (308 in the Flanders and 262 in the Walloon region) were invited by e-mail to participate in the study. After the fi rst mailing, another two mailings were performed. The data were collected using an online questionnaire with closed questions. PASW Statistics 18 was used for statistical analysis. RESULTS: The response rate in the Flemish region and Walloon region was respectively 57.47% and 16.41%. In Flanders, 94.9% of respondents reported that they organize health promotion initiatives, while in Wallonia this percentage was 65.1%. Most common organized initiatives in the Flanders region were sport (74.4%) and social welfare (46.4%) initiatives. In Wallonia most common initiatives were prevention of disease/vaccination (45.3%) and sport (44%). Both in Flanders and Wallonia, initiatives concerning mental health were little organized. In general, the initiatives aimed at certain high-risk groups such as persons with mental health problems, older and disabled persons were scarce. On the level of municipal policy lack of appropriate fi nancing was reported as the most common barrier for not organizing preventive strategies. CONCLUSIONS: On the level of municipal policy reinforcement of the value of preventive strategies concerning health promotion with appropriate fi nancing is required. When organizing preventive initiatives, special attention to reach certain high-risk groups will be needed.
PHP129
ATTITUDES OF HUNGARIAN POPULATION TOWARD CO-PAYMENTS
Baji P 1 , Pavlova M 2 , Gulacsi L 1 , Groot W 2 1 Corvinus University of Budapest, Budapest, Hungary; 2 University of Maastricht, Maastricht, The Netherlands OBJECTIVES: The issue of the introduction of co-payments is a great policy challenge in most of the Central-Eastern European countries. This is also the case in Hungary, where visit fee was introduced for health care services in 2007, and abolished one year later as a result of a referendum. The aim of our study is to identify different types of attitudes towards patient payments, and answer why visit fee was so unpopular among Hungarian population. METHODS: 8 focus-group discussions with health care consumers and physicians and 7 in-depth interviews with policy makers were conducted in Hungary during the summer 2009 on the attitude of patient payments in health care. RESULTS: Based on the transcripts and questionnaires fi lled in by all respondents during the focus group discussions and interviews three different groups of attitude were identifi ed. The group of "Supporters" support the introduction of patient payments with the aim of controlling the unnecessary use of services. The group of "Undecided" concern patient payments as an opportunity to provide additional resource for health care system by paying for "extra-better-quality services". "Sceptics" strongly refuse the idea of patient payments mainly referring to ethical issues. Consumers mainly belong to the group of "Undecided", while one part of the physicians belongs to "Supporters", the other part to "Sceptics". Policy makers are all belong to the group of "Supporters". CONCLUSIONS: Before the implementation of patient payments, mapping of population's attitude is inevitable. In Hungary the failure of the introduction of visit fee can be explained by different expectations of health care consumers. They are not against to pay for health care services, but expecting better quality of provided services in return.
PHP130 TRENDS IN COST CONTAINMENT MEASURES
Mukku S, Klein Lankhorst E, Edathodu AS Double Helix Consulting Group, London, UK OBJECTIVES: In the current economic climate health authorities are fi nding ways to control spending. a popular measure is the introduction of cost containment strategies for pharmaceuticals to lessen the burden of cost of drugs. The objective of this research was to analyze the importance of different cost containment measures that payers use in selected markets. The research extends to analyze the gaps between the policies on paper and the extent these are interpreted and executed in practice. METHODS: Interviews were conducted with payers at the national, regional and local level in selected European and non-European markets. RESULTS: All countries utilise different measures to control spending on pharmaceuticals. The measures that are used by markets include: internal therapeutic referencing, international price referencing, generic substitution, risk-sharing agreements, budget caps, profi t caps, index pricing, price cuts, rebates and price volume agreements. The critical fi nding from the research was that although combinations of measures are included in the national and regional policies, in reality their interpretation and execution varies substantially. For example, Spain uses internal referencing and price referencing at the national level, regions apply price discounts and rebates. Similarly, in the The Netherlands a preferred drug policy is introduced, which means that health insurers can now choose a preferred drug for reimbursement, which is usually the cheapest option of the reference basket. If the patient does not want this product, they have to pay the full price of the other product. Another European country which has become the recent focus is Germany; where price regulation will become dominant in the near future. There are uncertainties on achievable prices of drugs, one reason being there is lack of sophisticated systems in place that can monitor these measures. CONCLUSIONS: There are currently many developments in the area of cost containment of pharmaceuticals which will have a profound effect on the pharmaceutical industry.
